E@ECIPE
🔴 LIVE NOW: Strategic Autonomy and Europe's Shattered Single Market Tune in to our webinar with @MatBauerEcon,… https://t.co/6FyofdrGIdHow does Europe make #digital policy and how can it be improved? What role plays the #D9+ group? Read our paper an… https://t.co/3VGSwCfYH0📣 New Publication! Expectations of what a #UK outside of the #EU could achieve were exaggerated, but nonetheless,… https://t.co/NDYqfJvrJP📣 New Publication! Expectations of what a #UK outside of the #EU could achieve were exaggerated, but nonetheless, t… https://t.co/n6TsilU8UnWant to learn more about #StrategicAutonomy and 📌potential economic costs 📌asymmetries in impacts on small & large… https://t.co/yLub1PkaUE
  • FOLLOW ECIPE
x
Browse

Published

The European Commission’s pharmaceutical innovation incentives review is at risk of serious overreach

By: Guest Author 

Subjects: European Union Healthcare